公开(公告)号：US20130303590A1

公开(公告)日：2013-11-14

申请号：US13869635

申请日：2013-04-24

申请人： Elena Feinstein ,  Igor Mett

发明人： Elena Feinstein ,  Igor Mett

IPC分类号： C12N15/113

CPC分类号： C12N15/113 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2320/31 ,  C12N2310/3521

摘要： The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801L gene and/or protein.

摘要翻译： 本发明提供了基于RTP801L基因和/或蛋白质的抑制来治疗微血管病症，眼睛疾病呼吸系统疾病和听力障碍的新型分子，组合物，方法和用途。

公开(公告)号：US08444983B2

公开(公告)日：2013-05-21

申请号：US13255214

申请日：2010-03-23

申请人： Elena Feinstein

发明人： Elena Feinstein

IPC分类号： A61K51/10 ,  A61K49/16 ,  A61K39/395 ,  A61K39/44

CPC分类号： A61K47/6849 ,  A61K39/39541 ,  A61K39/39558 ,  A61K49/0058 ,  C07K16/2851 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/77 ,  C07K2317/92

摘要： The present invention provides antibodies or antigen-binding fragments thereof that specifically bind the ENDO180 polypeptide and are internalized thereby, to conjugates comprising the molecules, to compositions comprising the antibodies and conjugates and to methods of using the same for delivery of therapeutic agents to cells that express the ENDO180 polypeptide on the surface of the cell for treating cell proliferative diseases or disorders and fibrosis, and for controlling (modulating) tumor progression.

摘要翻译： 本发明提供了特异性结合ENDO180多肽并由此被内化至包含该分子的缀合物的抗体或其抗原结合片段与包含抗体和缀合物的组合物，以及使用该抗体或缀合物的方法将治疗剂递送至细胞 在细胞表面表达ENDO180多肽，用于治疗细胞增殖性疾病或病症和纤维化，并控制（调节）肿瘤进展。

公开(公告)号：US20130123334A1

公开(公告)日：2013-05-16

申请号：US13595519

申请日：2012-08-27

申请人： Elena Feinstein ,  Husevin Aygun ,  Rami Skaliter ,  Hagar Kalinski ,  Igor Mett ,  James McSwiggen ,  Leonid Beigelman

发明人： Elena Feinstein ,  Husevin Aygun ,  Rami Skaliter ,  Hagar Kalinski ,  Igor Mett ,  James McSwiggen ,  Leonid Beigelman

IPC分类号： C07H21/02

CPC分类号： C07H21/02 ,  C12N15/111 ,  C12N2310/14 ,  C12N2310/319 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/332 ,  C12N2310/346 ,  C12N2320/51 ,  C12N2310/3521

摘要： The invention relates to siRNA compounds possessing novel sequences and structural motifs which down-regulate the expression of specific human genes. The invention also relates to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The present invention also provides a method of treating and/or preventing the incidence or severity of various diseases or conditions associated with the genes and/or symptoms associated with such diseases or conditions comprising administering to a subject in need of treatment for such disease or condition and/or symptom the compound or the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the subject.

摘要翻译： 本发明涉及具有下调特定人基因表达的新型序列和结构基序的siRNA化合物。 本发明还涉及包含这些化合物和药学上可接受的载体的药物组合物。 本发明还提供了治疗和/或预防与这些疾病或病症相关的基因和/或症状相关的各种疾病或病症的发生率或严重程度的方法，包括向需要治疗的受试者施用此类疾病或病症 和/或治疗有效剂量的化合物或药物组合物的症状，从而治疗受试者。

公开(公告)号：US08309532B2

公开(公告)日：2012-11-13

申请号：US12803118

申请日：2010-06-17

申请人： Elena Feinstein ,  Jorg Kaufmann ,  Klaus Giese

发明人： Elena Feinstein ,  Jorg Kaufmann ,  Klaus Giese

IPC分类号： A61K31/70 ,  C07H21/02 ,  C07H21/04

CPC分类号： C07H21/02 ,  A01K2217/058 ,  A01K2267/0362 ,  A61K31/713 ,  A61K39/39541 ,  A61K45/06 ,  C12N15/113 ,  C12N2310/14 ,  C12N2310/321 ,  A61K2300/00 ,  C12N2310/3521

摘要： The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of the RTP801 gene and/or protein.

摘要翻译： 本发明提供了基于RTP801基因和/或蛋白质的抑制来治疗微血管病症，眼部疾病和呼吸病症的新型分子，组合物，方法和用途。

公开(公告)号：US08278287B2

公开(公告)日：2012-10-02

申请号：US12988307

申请日：2009-04-06

申请人： Elena Feinstein ,  Igor Mett ,  Hagar Kalinski

发明人： Elena Feinstein ,  Igor Mett ,  Hagar Kalinski

IPC分类号： A61K31/70 ,  C07H21/02 ,  C07H21/04

CPC分类号： C12N15/113 ,  C12N2310/14 ,  C12N2310/317 ,  C12N2310/319 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/332 ,  C12N2310/343 ,  C12N2310/344 ,  C12N2310/3521

摘要： The present invention provides chemically modified siRNA compounds that target the Nrf2 gene and pharmaceutical compositions comprising same useful for treating or preventing the incidence or severity of a cancerous disease, particularly various lung cancers.

摘要翻译： 本发明提供靶向Nrf2基因的化学修饰的siRNA化合物和包含用于治疗或预防癌性疾病，特别是各种肺癌的发病率或严重程度的药物组合物。

公开(公告)号：US08198258B2

公开(公告)日：2012-06-12

申请号：US13092501

申请日：2011-04-22

申请人： Orna Mor ,  Elena Feinstein

发明人： Orna Mor ,  Elena Feinstein

IPC分类号： A61K31/70 ,  C07H21/02 ,  C07H21/04 ,  C12Q1/68

CPC分类号： C07H21/04 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/76 ,  C12N9/1044 ,  C12N15/1137 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2310/322 ,  C12Y203/02013 ,  C12N2310/3527 ,  C12N2310/3521

摘要： The invention relates to a double-stranded compound, preferably an oligoribonucleotide (siRNA), which down-regulates the expression of a human TGaseII gene at the post-transcriptional level. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from a fibrotic disease such as pulmonary, kidney and liver fibrosis or ocular, scarring comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The invention also relates to treatment of fibrotic and other diseases by use of antibodies to TGaseII polypeptide.

摘要翻译： 本发明涉及在转录后水平下调人TGaseII基因表达的双链化合物，优选寡核糖核苷酸（siRNA）。 本发明还涉及包含该化合物或能够表达寡核糖核苷酸化合物的载体和药学上可接受的载体的药物组合物。 本发明还考虑了治疗患有纤维化疾病如肺，肾和肝纤维化或眼睛，瘢痕形成的患者的方法，其包括以治疗有效剂量向患者施用药物组合物，从而治疗患者。 本发明还涉及通过使用TGaseII多肽的抗体来治疗纤维化和其它疾病。

公开(公告)号：US20120108647A1

公开(公告)日：2012-05-03

申请号：US13218053

申请日：2011-08-25

申请人： Elena Feinstein ,  Igor Mett

发明人： Elena Feinstein ,  Igor Mett

IPC分类号： A61K31/7088 ,  A61P27/06 ,  A61P27/02 ,  A61K31/713 ,  C07H21/02

CPC分类号： C12N15/113 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2320/31 ,  C12N2310/3521

摘要： The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801L gene and/or protein.

摘要翻译： 本发明提供了基于RTP801L基因和/或蛋白质的抑制来治疗微血管病症，眼睛疾病呼吸系统疾病和听力障碍的新型分子，组合物，方法和用途。

公开(公告)号：US20110117102A1

公开(公告)日：2011-05-19

申请号：US12803118

申请日：2010-06-17

申请人： Elena Feinstein ,  Jorg Kaufmann ,  Klaus Giese

发明人： Elena Feinstein ,  Jorg Kaufmann ,  Klaus Giese

IPC分类号： A61K39/395 ,  A61K31/7088 ,  C07H21/02 ,  A61P27/06 ,  A61P11/00 ,  A61P27/02

CPC分类号： C07H21/02 ,  A01K2217/058 ,  A01K2267/0362 ,  A61K31/713 ,  A61K39/39541 ,  A61K45/06 ,  C12N15/113 ,  C12N2310/14 ,  C12N2310/321 ,  A61K2300/00 ,  C12N2310/3521

摘要： The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of the RTP801 gene and/or protein.

摘要翻译： 本发明提供了基于RTP801基因和/或蛋白质的抑制来治疗微血管病症，眼部疾病和呼吸病症的新型分子，组合物，方法和用途。

公开(公告)号：US07910566B2

公开(公告)日：2011-03-22

申请号：US12006722

申请日：2008-01-04

申请人： Elena Feinstein

发明人： Elena Feinstein

IPC分类号： A61K48/00 ,  C07H21/02 ,  C07H21/04

CPC分类号： A61K31/70

摘要： The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from acute renal failure or other kidney diseases comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient.

摘要翻译： 本发明涉及下调人p53基因表达的双链化合物，优选寡核糖核苷酸。 本发明还涉及包含该化合物或能够表达寡核糖核苷酸化合物的载体和药学上可接受的载体的药物组合物。 本发明还考虑了治疗患有急性肾衰竭或其它肾脏疾病的患者的方法，包括以治疗有效剂量向患者施用药物组合物，从而治疗患者。

公开(公告)号：US20110045499A1

公开(公告)日：2011-02-24

申请号：US12800738

申请日：2010-05-21

申请人： Roni Wechsler ,  Igor Mett ,  Elena Feinstein

发明人： Roni Wechsler ,  Igor Mett ,  Elena Feinstein

IPC分类号： G01N33/53

CPC分类号： G01N33/74 ,  G01N2500/02 ,  G01N2500/04 ,  G01N2500/10 ,  G01N2510/00

摘要： RTP801 represents a unique gene target for hypoxia-inducible factor-1 (HIF-1). Down-regulation of the mTOR pathway activity by hypoxia requires de novo mRNA synthesis and correlates with increased expression of RTP801.The present invention relates to screening systems utilizing RTP801 and/or RTP801 interactors to and/or RTP801 biological activity, to drug candidates identified by such screening systems, and to the use of such drug candidates in the treatment of various disorders.